On June 12, 2017, the U.S. Supreme Court ruled that biosimilar makers can give 180-day notice of commercial marketing prior to obtaining license from the FDA. Sandoz Inc. v. Amgen Inc., 582 U.S. __ (2017). Full text of the opinion is available here.
|
Disclaimer: The content in this blog is solely for informational purposes and does not constitute legal advice.
AuthorArchives
September 2017
Categories
All
|
RSS Feed
